Alzheimer's disease (AD) is a cognitive disease with high morbidity and mortality. In AD patients, the diversity of the gut microbiota is altered, which influences pathology through the gut鈥揵rain axis. Probiotic therapy alleviates pathological and psychological consequences by restoring the diversity...
Although several studies have been conducted to unravel the possible relationship between Alzheimer's Disease (AD) pathogenesis and progression, the diagnostic and therapeutic potential of approaches aiming at restoring gut microbiota eubiosis remain to be fully addressed. In this narrative review, we ...
Alzheimer’s disease bile acids microbiota–gut–brain axis molecular mechanism therapeutic strategy 1. Introduction Alzheimer’s disease (AD) is a neurodegenerative disorder with a high incidence and high disability rate among the elderly, affecting over 50 million individuals worldwide. This number is...
University of Nevada, Las Vegas, researchers have identified a correlation between Alzheimer's disease and specific gut microbiota populations. In a paper published inScientific Reportstitled "Genetic correlations between Alzheimer's disease and gut microbiome genera," the researchers explain how they nar...
Alzheimer’s disease (AD) is the most common form of dementia without effective clinical treatment. Here, we show that intermittent fasting (IF) improves cognitive functions and AD-like pathology in a transgenic AD mouse model (5XFAD). IF alters gut micr
Alzheimer’s disease (AD) is a progressive, clinically heterogeneous, age-sensitive neurodegenerative disease, characterised by often escalating impairments of memory and other cognitive functions together with associated changes in personality and behaviour [1,2,3]. Amyloid plaques and neurofibrillary tangl...
The objective of this study is to characterize the impact of the gut microbiota on ketamine metabolism and using these metabolites understand how ketamine can be used as a therapeutic for neuroinflammation associated with Alzheimer's disease (AD). Using an in vitro model of the human ...
The genetic, clinical and anatomical presentation of Alzheimer's disease (AD) is extremely heterogenous. Although increasing evidences show that alterations in the gut microbiota (GMB) composition are involved in AD, their contribution to AD pathology remain unclear. The aim of this study is to ...
Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer’s disease (AD) is increasingly being recognized. However, knowledge about alterations of gut microbiota in preclinical AD,
The microbiota–gut–brain axis ISSN: 1758-9193 (Online) In this topical collection (1 articles) Research Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study Can Sheng, Kun...